Pulmonary embolism is the third most common cause of cardiovascular death and accounts for almost 100,000 deaths each year in India. Recurrence is likely to occur in 30% of patients within 10 years in the form of a new embolism. Hence, appropriate use of thrombolytic agents and individualized management plan is essential for better patient outcomes and prevent recurrence. A new class of drugs known as PCSK9 inhibitors is recently approved by USFDA, these drugs lower LDL levels in the body and prevent heart attacks or strokes.
These drugs can effectively prevent the formation of emboli, as well as its associated cardiovascular complications if used appropriately. To help doctors know more about these recent advancements in cardiovascular disease management, Docplexus has organized an interactive case-based session on 20th July 2020, 7:00 PM onwards . In this session, experts from the…
